View Clinical Trial (Medical Research Study)

Long Term Study of Canakinumab (ACZ885) in Patients With Gout - NCT00927810-66606(Clinical Trial 299624)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Topeka
State:  
KS
Zip Code: 66606
Conditions: Gout
Purpose: This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.
Study summary:
Criteria: Inclusion Criteria: - Patients who completed the core study CACZ885H2251. A patient is defined as completing the core study if he/she completed the study up to and including the last visit (Visit 9). - Patients who have signed a written informed consent before any trial procedure is performed. Exclusion Criteria: - Patients for whom continuation in the extension 1 is not considered appropriate by the treating physician. - Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (serum or urine). Other protocol defined inclusion/exclusion criteria may apply
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 16, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.